This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

China Biologic Products Eyes Global Market

The recently sat down with Ming Yin, head of investor relations and vice president of finance for China Biologic Products (CBPO - Get Report).

China Biologics is the leading public plasma-based products manufacturer in China. The company saw its sales grow from $4 million in 2002 to $119 million in 2009 and is planning to expand its products into the world plasma markets.

Can you give me some background on your company?

China Biologic entered the United States capital markets in 2006. Our decision was largely prompted by the Chinese government's decision to start privatizing plasma collection centers, and we needed immediate capital to pursue strategic acquisition opportunities

Before 2008, China Biologic had one operating subsidiary, Shandong Taibang. By the end of 2008, we had completed two acquisitions with the purchase of a majority ownership in Guiyang Dalin and a 35% equity interest in Xi'an Huitian. With those two acquisitions, China Biologic became the largest non-state owned company in China's plasma industry.

Where do you see the company in five years? 10 years?

Until recently, we were a small plasma-based products manufacturer. In the next five years we will continue to execute a similar strategy through organic growth and pursuit of additional suitable strategic acquisitions to increase our market share in China.

In the next five to 10 years, we want to have more global presence in the world plasma-based product markets. We view US-based Baxter (BAX - Get Report) and Australian company CSL as our models for expansion.

What are the various segment lines of the company?

We have a fully integrated plasma business with the main products of Human Albumin Human Immunoglobulin for Intravenous Injection, and various hyper-immune products. We have more products in the pipeline, including Human Prothrombin Complex Concentrate and Human Coagulation Factor VIII. Our current revenues are mainly from the plasma protein derivatives, which is our core business and our strength.

Who are your main competitors?

In China, our main competitors are Shanghai RAAS Blood Products, Hualan Biological Engineering and Beijing Tiantan Biological Products. Internationally, we face competition from CSL and Baxter because they all are selling their human albumin products in China. We believe international companies will have limited opportunities in China in the future as they only have permission to sell Human albumin products.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AXN $0.80 3.91%
BAX $44.76 0.12%
CBPO $117.51 -2.40%
MR $27.94 0.25%
AAPL $95.34 1.80%


Chart of I:DJI
DOW 17,771.66 -119.50 -0.67%
S&P 500 2,063.80 -17.63 -0.85%
NASDAQ 4,773.2230 -44.3710 -0.92%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs